111 related articles for article (PubMed ID: 15056953)
1. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors IV. A series of new derivatives containing a spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one skeleton.
Nishida H; Mukaihira T; Saitoh F; Harada K; Fukui M; Matsusue T; Okamoto A; Hosaka Y; Matsumoto M; Shiromizu I; Ohnishi S; Mochizuki H
Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):406-12. PubMed ID: 15056953
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors V. A series of new derivatives containing a spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one scaffold.
Saitoh F; Mukaihira T; Nishida H; Satoh T; Okano A; Yumiya Y; Ohkouchi M; Johka R; Matsusue T; Shiromizu I; Hosaka Y; Matsumoto M; Ohnishi S
Chem Pharm Bull (Tokyo); 2006 Nov; 54(11):1535-44. PubMed ID: 17077550
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor.
Nishida H; Miyazaki Y; Kitamura Y; Ohashi M; Matsusue T; Okamoto A; Hosaka Y; Ohnishi S; Mochizuki H
Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1237-44. PubMed ID: 11605647
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities.
Nishida H; Miyazaki Y; Mukaihira T; Saitoh F; Fukui M; Harada K; Itoh M; Muraoka A; Matsusue T; Okamoto A; Hosaka Y; Matsumoto M; Ohnishi S; Mochizuki H
Chem Pharm Bull (Tokyo); 2002 Sep; 50(9):1187-94. PubMed ID: 12237534
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors(1-6) VI. A series of new derivatives containing N,S- and N,SO2-spiro acetal scaffolds.
Saitoh F; Nishida H; Mukaihira T; Kosuga N; Ohkouchi M; Matsusue T; Shiromizu I; Hosaka Y; Matsumoto M; Yamamoto I
Chem Pharm Bull (Tokyo); 2007 Feb; 55(2):317-23. PubMed ID: 17268108
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.
Arnaiz DO; Zhao Z; Liang A; Trinh L; Witlow M; Koovakkat SK; Shaw KJ
Bioorg Med Chem Lett; 2000 May; 10(9):957-61. PubMed ID: 10853668
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors III. Effect of ring opening of piperazinone moiety on inhibition.
Nishida H; Miyazaki Y; Mukaihira T; Shimada H; Suzuki K; Saitoh F; Mizuno M; Matsusue T; Okamoto A; Hosaka Y; Matsumoto M; Ohnishi S; Mochizuki H
Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):459-62. PubMed ID: 15056966
[TBL] [Abstract][Full Text] [Related]
8. Cinnamyl derivatives: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
Chem Pharm Bull (Tokyo); 2008 Jun; 56(6):758-70. PubMed ID: 18520077
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.
Zhao Z; Arnaiz DO; Griedel B; Sakata S; Dallas JL; Whitlow M; Trinh L; Post J; Liang A; Morrissey MM; Shaw KJ
Bioorg Med Chem Lett; 2000 May; 10(9):963-6. PubMed ID: 10853669
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR
J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.
Buckman BO; Mohan R; Koovakkat S; Liang A; Trinh L; Morrissey MM
Bioorg Med Chem Lett; 1998 Aug; 8(16):2235-40. PubMed ID: 9873520
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the factor Xa inhibitor, ZK 807834 (CI-1031).
Light DR; Guilford WJ
Curr Top Med Chem; 2001 Jun; 1(2):121-36. PubMed ID: 11899248
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors.
Huang W; Zhang P; Zuckett JF; Wang L; Woolfrey J; Song Y; Jia ZJ; Clizbe LA; Su T; Tran K; Huang B; Wong P; Sinha U; Park G; Reed A; Malinowski J; Hollenbach SJ; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2003 Feb; 13(3):561-6. PubMed ID: 12565972
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of the thrombin selectivity of a ligand that contains the constrained arginine mimic (2S)-2-amino-(3S)-3-(1-carbamimidoyl- piperidin-3-yl)-propanoic acid at P1.
Narasimhan LS; Rubin JR; Holland DR; Plummer JS; Rapundalo ST; Edmunds JE; St-Denis Y; Siddiqui MA; Humblet C
J Med Chem; 2000 Feb; 43(3):361-8. PubMed ID: 10669563
[TBL] [Abstract][Full Text] [Related]
16. Cinnamylindoline derivatives: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1494-504. PubMed ID: 17917295
[TBL] [Abstract][Full Text] [Related]
17. Nonbenzamidine tetrazole derivatives as factor Xa inhibitors.
Quan ML; Ellis CD; He MY; Liauw AY; Woerner FJ; Alexander RS; Knabb RM; Lam PY; Luettgen JM; Wong PC; Wright MR; Wexler RR
Bioorg Med Chem Lett; 2003 Feb; 13(3):369-73. PubMed ID: 12565931
[TBL] [Abstract][Full Text] [Related]
18. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.
Dudley DA; Bunker AM; Chi L; Cody WL; Holland DR; Ignasiak DP; Janiczek-Dolphin N; McClanahan TB; Mertz TE; Narasimhan LS; Rapundalo ST; Trautschold JA; Van Huis CA; Edmunds JJ
J Med Chem; 2000 Nov; 43(22):4063-70. PubMed ID: 11063603
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.
Hirayama F; Koshio H; Katayama N; Ishihara T; Kaizawa H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kurihara H; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2003 Feb; 11(3):367-81. PubMed ID: 12517432
[TBL] [Abstract][Full Text] [Related]
20. Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents.
Ries UJ; Priepke HW; Hauel NH; Handschuh S; Mihm G; Stassen JM; Wienen W; Nar H
Bioorg Med Chem Lett; 2003 Jul; 13(14):2297-302. PubMed ID: 12824021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
